Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC). Varner says the data were presented in two presentations at the 2021 American Association of Cancer Research (AACR) annual meeting. The positive data is helpful for Genprex’s plan to launch a pair of upcoming clinical trials.
Genprex presents positive preclinical data for lung cancer drug REQORSA at AACR annual meeting
